Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.46 |
| ▸ | ESR1 | P03372 | 8/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17542386 | 0.77 | KDM1A (0.53) | KDM1AESR2ESR1SIGMAR1KDM4C | |
| SCHEMBL2498788 | 0.77 | ESR2 (0.51) | KDM1AESR2ESR1SIGMAR1 | |
| SCHEMBL21124762 | 0.74 | KDM1A (0.52) | KDM1AESR2ESR1SIGMAR1KDM4C | |
| Hydrochloric Acid SCHEMBL20522854 | 0.72 | KDM1A (0.51) | KDM1AESR2ESR1SIGMAR1KDM4C | |
| SCHEMBL26194433 | 0.72 | KDM1A (0.48) | KDM1AESR2ESR1SIGMAR1KDM4C | |
| SCHEMBL23443007 | 0.72 | KDM1A (0.48) | KDM1ASIGMAR1KDM4CSLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL20522853 | 0.72 | KDM1A (0.51) | KDM1AESR2ESR1SIGMAR1KDM4C | |
| SCHEMBL28883100 | 0.72 | KDM1A (0.57) | KDM1ASIGMAR1KDM4C | |
| SCHEMBL20246537 | 0.71 | KDM4E (0.35) | KDM1AESR2ESR1 | |
| SCHEMBL3863719 | 0.71 | ESR2 (0.46) | KDM1AESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762393-B1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-3762393-B1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | AMGEN INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210047344-A1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20210047344-A1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC. (US) | 2021-02-18 | — | — | US | disclosed |
| WO-2019173181-A1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | AMGEN INC. (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047344-A1 | ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS | MCL1, BCL2A1, BCLAF1 | KDM1A 786/4885ESR2 2852/4885ESR1 3970/4885 |
| US-11274105-B2 | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | MCL1, BCL2A1, BCLAF1 | KDM1A 786/4885ESR2 2852/4885ESR1 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.